| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1035038918 |
| P356 | DOI | 10.1007/S00262-009-0792-6 |
| P932 | PMC publication ID | 3070377 |
| P698 | PubMed publication ID | 19921513 |
| P5875 | ResearchGate publication ID | 38097270 |
| P50 | author | Mohamed L. Salem | Q52145954 |
| P2093 | author name string | David J Cole | |
| P2860 | cites work | Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor | Q22008006 |
| Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells | Q24530100 | ||
| Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells | Q24540135 | ||
| CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. | Q24540429 | ||
| Adoptive immunotherapy for cancer: building on success | Q24546258 | ||
| IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells | Q24621753 | ||
| Adoptive cell transfer: a clinical path to effective cancer immunotherapy | Q24644774 | ||
| Myeloid-derived suppressor cells as regulators of the immune system | Q28131637 | ||
| Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice | Q28377964 | ||
| Subsets of myeloid-derived suppressor cells in tumor-bearing mice | Q29614297 | ||
| Molecular identification of a danger signal that alerts the immune system to dying cells | Q29619497 | ||
| Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy | Q29619961 | ||
| Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo | Q33653210 | ||
| Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells | Q33707270 | ||
| In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy | Q33756565 | ||
| Natural adjuvants: endogenous activators of dendritic cells | Q33878894 | ||
| Apoptosis, cross-presentation, and the fate of the antigen specific immune response. | Q34167296 | ||
| Progress in human tumour immunology and immunotherapy | Q34253585 | ||
| Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation | Q34326827 | ||
| Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. | Q34422330 | ||
| Cytokines as a link between innate and adaptive antitumor immunity. | Q34581798 | ||
| Interleukin-2-dependent mechanisms of tolerance and immunity in vivo | Q34655265 | ||
| Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells. | Q34732294 | ||
| Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C) | Q34732473 | ||
| CD8+ T-cell memory in tumor immunology and immunotherapy | Q34768139 | ||
| Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model | Q34770289 | ||
| Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model | Q34887495 | ||
| The in vivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumor. | Q34999698 | ||
| Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination | Q35012887 | ||
| Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? | Q35594089 | ||
| Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells | Q35613477 | ||
| Ligands for L-selectin: homing, inflammation, and beyond | Q35698423 | ||
| A sense of danger from radiation. | Q35820333 | ||
| Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. | Q35901034 | ||
| Transfer of antigen between migrating and lymph node-resident DCs in peripheral T-cell tolerance and immunity | Q35941910 | ||
| Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization | Q36027708 | ||
| Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. | Q36070720 | ||
| Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy | Q36108095 | ||
| Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model. | Q36121187 | ||
| Induced sensitization of tumor stroma leads to eradication of established cancer by T cells | Q36228950 | ||
| Toll-like receptors in tumor immunotherapy | Q36253608 | ||
| Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2 | Q36346766 | ||
| Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming | Q36371607 | ||
| Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. | Q36371632 | ||
| T cells compete for access to antigen-bearing antigen-presenting cells | Q36376071 | ||
| gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand | Q36401461 | ||
| Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. | Q36402501 | ||
| Translating innate immunity into immunological memory: implications for vaccine development | Q36404657 | ||
| T-cell receptor gene therapy of established tumors in a murine melanoma model | Q36449599 | ||
| Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. | Q36456753 | ||
| Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. | Q36456769 | ||
| Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant | Q36459340 | ||
| Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha | Q36470718 | ||
| Dendritic cells in a mature age. | Q36475977 | ||
| Reshaping the past: Strategies for modulating T-cell memory immune responses. | Q36568931 | ||
| Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens | Q36622359 | ||
| Roles of sulfated glycans in lymphocyte homing | Q36672292 | ||
| IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy | Q36677310 | ||
| Molecular characteristics of immunogenic cancer cell death. | Q37002804 | ||
| Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain | Q37037932 | ||
| Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer | Q37051019 | ||
| Chemotherapy followed by syngeneic dendritic cell injection in the mouse: findings and implications for human treatment | Q37056817 | ||
| Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy | Q37116373 | ||
| Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. | Q37118160 | ||
| Combined modality immunotherapy and chemotherapy: a new perspective | Q37167300 | ||
| Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide | Q37186715 | ||
| OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. | Q37273138 | ||
| Immunogenic cell death modalities and their impact on cancer treatment | Q37368966 | ||
| Regulatory myeloid suppressor cells in health and disease | Q37373257 | ||
| Myeloid-derived suppressor cells: a novel therapeutic target | Q37393000 | ||
| CpG oligodeoxynucleotides as immunotherapy in cancer. | Q38570179 | ||
| Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease | Q39737912 | ||
| Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice | Q39797630 | ||
| Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma | Q39893082 | ||
| Anti-tumour effects of exosomes in combination with cyclophosphamide and polyinosinic-polycytidylic acid | Q39903777 | ||
| Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy. | Q39961463 | ||
| Activation and route of administration both determine the ability of bone marrow-derived dendritic cells to accumulate in secondary lymphoid organs and prime CD8+ T cells against tumors | Q40111834 | ||
| Radiation-induced apoptosis along with local and systemic cytokine elaboration is associated with DC plus radiotherapy-mediated renal cell tumor regression | Q40142911 | ||
| Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration | Q40178764 | ||
| Cutting edge: elimination of an endogenous adjuvant reduces the activation of CD8 T lymphocytes to transplanted cells and in an autoimmune diabetes model | Q40302449 | ||
| Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL. | Q40872634 | ||
| Immediate-early, transient induction of the interleukin-1 beta gene in mouse spleen macrophages by ionizing radiation | Q41343263 | ||
| Tumor rejection by disturbing tumor stroma cell interactions | Q42944518 | ||
| Cyclophosphamide/granulocyte colony-stimulating factor causes selective mobilization of bone marrow hematopoietic stem cells into the blood after M phase of the cell cycle | Q43567029 | ||
| Alterations in dendritic cell phenotype and function associated with immunoenhancing effects of a subcutaneously administered cyclophosphamide derivative | Q43618750 | ||
| Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. | Q43770332 | ||
| Priming of CTLs by lymphocytic choriomeningitis virus depends on dendritic cells | Q43845179 | ||
| Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy | Q44163505 | ||
| Effects of cyclophosphamide and soluble tumor-associated antigens on lymphoid infiltration, proliferative activity and rate of apoptosis in chemically-induced rat mammary tumors | Q44258086 | ||
| Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer | Q44527902 | ||
| Irradiation up-regulates CD80 expression through two different mechanisms in spleen B cells, B lymphoma cells, and dendritic cells | Q44899128 | ||
| Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity | Q44963979 | ||
| Uric acid promotes tumor immune rejection | Q45003959 | ||
| The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand | Q45072204 | ||
| Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer | Q45790670 | ||
| Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. | Q45972793 | ||
| Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells | Q46081589 | ||
| Cyclophosphamide decreases the number, percentage and the function of CD25+ CD4+ regulatory T cells, which suppress induction of contact hypersensitivity | Q46495467 | ||
| Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. | Q46511479 | ||
| Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma | Q46662100 | ||
| X-ray-induced P-selectin localization to the lumen of tumor blood vessels | Q48346185 | ||
| CD11chigh dendritic cell ablation impairs lymphopenia-driven proliferation of naive and memory CD8+ T cells. | Q51987412 | ||
| Cutting edge: differential self-peptide/MHC requirement for maintaining CD8 T cell function versus homeostatic proliferation. | Q51988170 | ||
| Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. | Q52006526 | ||
| CD8+ memory T cells (CD44high, Ly-6C+) are more sensitive than naive cells to (CD44low, Ly-6C-) to TCR/CD8 signaling in response to antigen. | Q52040001 | ||
| Anamnestic responses induced by antigen persisting on follicular dendritic cells from cyclophosphamide-treated mice. | Q52211900 | ||
| Response of the immune system of mammary tumor-bearing rats to cyclophosphamide and soluble low-molecular-mass tumor-associated antigens: the bone marrow and thymus. | Q53386805 | ||
| Response of the immune system of mammary tumor-bearing rats to cyclophosphamide and soluble low-molecular-mass tumor-associated antigens: rate of lymphoid infiltration and distribution of T lymphocytes in tumors. | Q53391717 | ||
| Importance of signaling via the IFN-alpha/beta receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor. | Q53854175 | ||
| Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism. | Q54009397 | ||
| Cyclophosphamide-induced bacterial translocation in Escherichia coli C25-monoassociated specific pathogen-free mice. | Q54573207 | ||
| Candida albicans infection enhances immunosuppression induced by cyclophosphamide by selective priming of suppressive myeloid progenitors for NO production | Q57080076 | ||
| Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expression | Q57252639 | ||
| Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration | Q57779785 | ||
| Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines | Q58326930 | ||
| Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine | Q61788033 | ||
| Kinetics of dendritic cells reconstitution and costimulatory molecules expression after myeloablative allogeneic haematopoetic stem cell transplantation: Implications for the development of acute graft-versus host disease | Q61939939 | ||
| Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells | Q66878121 | ||
| Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report | Q68100559 | ||
| Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2 | Q70396686 | ||
| Expression of IL-1 beta mRNA in mice after whole body X-irradiation | Q71513741 | ||
| Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor | Q72075255 | ||
| Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice | Q72372127 | ||
| Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection | Q73128948 | ||
| Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation | Q73272095 | ||
| Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer | Q73311980 | ||
| The granulocyte colony-stimulating factor receptor is required for the mobilization of murine hematopoietic progenitors into peripheral blood by cyclophosphamide or interleukin-8 but not flt-3 ligand | Q73774723 | ||
| Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells | Q73939950 | ||
| CD34+ immune suppressive cells in the peripheral blood of patients with head and neck cancer | Q74232367 | ||
| Cyclophosphamide enhances the CTL precursor frequency in mice immunized with MUC1-mannan fusion protein (M-FP) | Q74462400 | ||
| Accumulation of P-selectin in the lumen of irradiated blood vessels | Q77921698 | ||
| Total lymphoid irradiation nonmyeloablative preconditioning enriches for IL-4-producing CD4+-TNK cells and skews differentiation of immunocompetent donor CD4+ cells | Q78447807 | ||
| Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells | Q79467930 | ||
| Activated circulating dendritic cells after hematopoietic stem cell transplantation predict acute graft-versus-host disease | Q80220196 | ||
| Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system | Q81310240 | ||
| Sequential expression of adhesion and costimulatory molecules in graft-versus-host disease target organs after murine bone marrow transplantation across minor histocompatibility antigen barriers | Q81676892 | ||
| MHC class I-positive dendritic cells (DC) control CD8 T cell homeostasis in vivo: T cell lymphopenia as a prerequisite for DC-mediated homeostatic proliferation of naive CD8 T cells | Q81880335 | ||
| No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF | Q83218256 | ||
| Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine | Q83314104 | ||
| The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu | Q83356122 | ||
| Adoptive T cell therapy of cancer | Q83574527 | ||
| P433 | issue | 3 | |
| P921 | main subject | dendritic cell | Q506253 |
| P304 | page(s) | 341-353 | |
| P577 | publication date | 2009-11-18 | |
| P1433 | published in | Cancer Immunology, Immunotherapy | Q5031409 |
| P1476 | title | Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination | |
| P478 | volume | 59 |
| Q42229717 | Absence of CD4 T-cell help provides a robust CD8 T-cell response while inducing effective memory in a preclinical model of melanoma |
| Q37776660 | Advances in Cellular Therapy for the Treatment of Thyroid Cancer |
| Q84563059 | Anti-tumor immune responses in immune-reconstituted mice injected with a tumor vaccine |
| Q36198098 | Chemotherapy plus dendritic cells co-cultured with cytokine-induced killer cells versus chemotherapy alone to treat advanced non-small-cell lung cancer: A meta-analysis |
| Q37772085 | Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience |
| Q37861216 | Current status and future applications of cellular therapies for cancer |
| Q36193963 | Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host. |
| Q36863949 | Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization |
| Q38003153 | Positron emission tomography reporter genes and reporter probes: gene and cell therapy applications. |
| Q38149916 | Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions |
| Q35975381 | Whole cell vaccines--past progress and future strategies |
Search more.